Therapie des Diabetes bei Herzinsuffizienz

ZUSAMMENFASSUNG

Es besteht mittlerweile eine sehr gute Evidenz dafür, dass Herzinsuffizienzereignisse bei Patienten mit Diabetes durch eine SGLT2-Inhibition verhindert werden können. Da die Herzinsuffizienz ein häufiges und schwerwiegendes Ereignis bei Diabetes darstellt, sollten die Präparate bei Patienten mit hohem kardiovaskulärem Risiko regelhaft zum Einsatz kommen, um so eine Verbesserung der Prognose zu erreichen.

• Literatur

• 1 Lepore JJ, Olson E, Demopoulos L. et al Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction.. JACC Heart Fail 2016; 4: 559-566 doi: 10.1016/j.jchf.2016.01.008
• 2 Jorsal A, Kistorp C, Holmager P. et al Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE) – a multicentre, double-blind, randomised, placebo-controlled trial.. Eur J Heart Fail 2017; 19: 69-77 doi: 10.1002/ejhf.657
• 3 Margulies KB, Hernandez AF, Redfield MM. et al Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial.. JAMA 2016; 316: 500-508 doi: 10.1001/jama.2016.10260
• 4 Zinman B, Wanner C, Lachin JM. et al Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.. N Engl J Med 2015; 373 (22) 2117-28 doi: 10.1056/NEJMoa1504720
• 5 Neal B, Perkovic V, Mahaffey KW. et al Canagliflozin and cardiovascular and renal events in type 2 diabetes.. N Engl J Med 2017; 377: 644-657 doi: 10.1056/NEJMoa1611925
• 6 Wiviott SD, Raz I, Bonaca MP. et al Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2018. Nov 10doi: 10.1056/NEJMoa1812389
• 7 Zelniker TA, Wiviott SD, Raz I. et al SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.. Lancet 2019; 393: 31-39 doi: 10.1016/S0140-6736(18)32590-X
• 8 Januzzi Jr JL, Butler J, Jarolim P. et al Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes.. J Am Coll Cardiol 2017; 70: 704-712 doi: 10.1016/j.jacc.2017.06.016
• 9 Soga F, Tanaka H, Tatsumi K. et al Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure.. Cardiovasc Diabetol 2018; 17: 132 doi: 10.1186/s12933-018-0775-z
• 10 Hallow KM, Helmlinger G, Greasley PJ. et al Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis.. Diabetes Obes Metab 2018; 20: 479-487 doi: 10.1111/dom.13126
• 11 Verma S, Rawat S, Ho KL. et al Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors.. JACC Basic Transl Sci 2018; 3: 575-587 doi: 10.1016/j.jacbts.2018.07.006
• 12 Kumar N, Garg A, Bhatt DL. et al Empagliflozin improves cardiorespiratory fitness in type 2 diabetes: translational implications.. Can J Physiol Pharmacol 2018; 96: 1184-1187 doi: 10.1139/cjpp-2018-0359